Epimab Biotherapeutics

Bispecific antibody therapies using its proprietary FIT-Ig platform

placeShanghai, Shanghai, China calendar_todayFounded 2015 groups49 employees language epimab.com

Innovation

5 patent families (4 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 1,292 times.

YearFilings
20151
20161
20172
20183
20193
20204
20212
20222
20234
20243
20251
20261

Investor mix

16 investors on record; lead investors include SDIC Innovation, Sherpa Venture Capital, Yuanhe Holdings, CMB International Capital.

Investor typeCountShare
Venture capital850%
Private equity319%
Bank & private debt213%
Other / undisclosed319%
Coming soon